Resources

Illuminating the latest from Solici

We shine a light on what’s going on at Solici and across the wider life science industry.

Filter resources

The Many Facets of Sustainability in Pharma

The pharma industry environmental impact The health sector is responsible for 4.4% of the global...

Latest

Who Funds The (Women’s Health) World? Girls.

Caveat – any reference to female/ woman, is based on the biological and physiological characteristics...

Treatment precision: will alpha-emitters change the radioligand therapy landscape in prostate and neuroendocrine cancers?

  Radioligand therapies (RLTs), in contrast to traditional treatment methods, have the potential to target...

The Copycat Market: Season of Migration to the East?

For a period, the regulated copycat market enjoyed the entry of large innovator pharma who...

Jeanne Penn joins Cambridge Healthcare Research as Vice President, US Commercial for Solici

Jeanne Penn has been appointed as Vice President, US Commercial for Solici, the strategic competitive...

Bispecifics: A breath of fresh air for th2 respiratory disease?

Current biological approaches for Th2 respiratory disease, and in particular, severe asthma, target individual cytokines...

Inflammatory Bowl Disease (IBD): Who is your money on?

The current mainstay treatments for IBD include immunomodulators (methotrexate and thiopurines), biologics (TNF-α being the...

Cinderella 2: Unlocking the value chain in antibiotic development to achieve market success

Brendan Walkden, Head of Solici, was the guest columnist at The Evidence Base earlier this...

Triple threat: Is the era of trispecific biologics upon us in Immunology?

The landscape of immunology and inflammation therapeutics is on the brink of a thrilling transformation...

Flashing a Spotlight on the ‘Hot’ Topic of Menopause

How many underserved mass markets remain in healthcare today? Amidst the femtech boom and a...

Is Rheumatoid Arthritis going to have a déjà vu moment?

The next big disruptor in Rheumatoid Arthritis (RA) may be a TNF. This statement may...

Gene Therapy and nAMD: Can We Move Beyond the Needle?

Access the PDF here...

The mRNA revolution: How 30 years of research sparked an overnight success

In light of the recent attention drawn to mRNA-based vaccines, it is crucial to recognize...

Tech to Triumph: Can the Technology Shape Gene Therapy Success?

As outlined in the previous instalments of this series, the rare disease gene replacement technology...

Advancing the Cure: The Road to Accessible SCD Therapies

Transitioning from treatment to cure Characterized by defective hemoglobin that causes Red Blood Cells (RBC)...

Prostate Cancer Q&A: ‘See’quencing the future of treatment options

ASCO 2024 will soon be upon us, bringing unfortunate news on the prostate cancer front:...

ASCO 2024: Are you ready for the Oncology Event-of-the-Year? 

Will the perioperative NSCLC data aid in patient selection or bring out a winner? Following...

Gene Therapy and nAMD: Can We Move Beyond the Needle?

Neovascular Age-Related Macular Degeneration (nAMD) is a leading cause of vision impairment and blindness among...

The changing seasons of Rheumatoid Arthritis – can RA drugs bloom again?

As flowers bloom and nature welcomes spring in the Northern Hemisphere, we are amidst a...

Who let the Gene Therapies out? Unleashing GTs’ Power in Rare Disorders

Groundbreaking scientific advancement in gene replacement technologies [GTs] has resulted in an ever-increasing number of...

Tipping the scales in Obesity – are GLP-1R developers overreaching?

The Pythagorean cup* of GLP-1Rs  As the pharmaceutical landscape buzzes with the acclaim of GLP-1Rs...

Contraceptives: is current policy hiding a golden opportunity?

Caveat – any reference to female/ woman and male/ man, is based on the biological...

Redefining Precision – The Next Chapter in ADC Optimization

As discussed in the first instalment of this series, antibody-drug conjugates (ADCs) have revolutionized the...

The ABC of ADCs

Back in March 2023, Pfizer announced its intention to acquire the Antibody Drug Conjugate [ADC]...

Unlocking Migraine Prevention: A 5-Year Journey Through the CGRP Revolution and a Look Towards What’s Next

For anyone following the migraine space, 2018 was poised to be a year of big...

Contact us

Reach out to us if you’d like to partner with us, want to join our team or would benefit from a conversation about how we shape the smartest choices in healthcare.

Get in touch